June 13, 2020
Little Eyedrop
June 13, 2020


LATTE Dosage Trial

The most effective and best tolerated dose of caffeine to reduce intermittent hypoxaemia

Research has led to improvements in neurodevelopmental outcomes for infants born very preterm, but there has been little research on long-term neurodevelopmental outcomes for infants born late preterm.  In very preterm infants, both apnoea and intermittent hypoxaemia are common and are associated with worse neurodevelopmental outcomes.  Caffeine has been shown to improve intermittent hypoxaemia in very preterm infants, but there are no data to show if this is the case in late preterm infants.  This trial is designed to determine the safest and most effective dose of caffeine in late preterm infants before wider studies to investigate the effects of caffeine on neurodevelopment in this group can be initiated.

Status: Recruitment completed

Sites: Auckland, Middlemore

ANZCTR number: ACTRN12618001745235